AZN is apparently getting the most buzz at ASCO; these are PRs for three presentations: https://www.businesswire.com/news/home/20240602348345/en (Tagrisso in Stage-III NSCLC) https://www.businesswire.com/news/home/20240602661484/en (Enhertu in HR+/HER2-low/ultralow metastatic breast cancer) https://www.businesswire.com/news/home/20240602058478/en (Imfinzi in LS-SCLC)